 |
|
 |
Biotechnology |
|
|
ADME/TOX Technologies
Publication Date January 2008
Publisher RI Technologies
Product Type Report
Pages 182
ISBN Number not applicable
Product Code RIT001
|
|
|
Summary
This market insight report on ADME/Tox Technologies covers both products and services used in the ADME/TOX industry. Predictive technologies analyzed include In vivo, In vitro, and In silico. Related technologies such as High Throughput Screening (HTS), and cell based assays are also analyzed. Market projections and estimates are illustrated by region and by technology.
The report serves as a guide to ADME/Tox industry, covering 341 companies that are engaged in ADME/Tox studies/screening, products and services. Major Contract Research Organizations serving ADME/Tox industry are also covered in the corporate directory section of this report. Information related to recent product releases, product developments, partnerships, collaborations, and mergers and acquisitions is covered in the report. A global perspective is presented along with regional analysis covering the regions of North America, Europe, Asia-Pacific, Latin America, the Middle East and Africa with 145 exclusive graphically represented exhibits.
|
Content
- I. Scope And Methodology
- II. Report Synopsis
- 1. Adme/Tox Technologies
- Absorption
- Distribution
- Metabolism
- Excretion
- Toxicity
- 2. Significant Methods for ADME/Tox
- Predictive Technologies
- Other Related ADME/Tox Methods
- 3. ADME/Tox Technologies - Global Market Analysis
- Exhibit 1: ADME/Tox Technologies (2005-2012) - Global Market Analysis
- (Current & Future) in US$ Billion (Graphical Representation included)
- Analysis by Technology
- In Vivo ADME/Tox - An Ever Growing Technology
- Global Market Analysis
- Exhibit 2: In Vivo ADME/Tox (2005-2012) - Global Market Analysis (Current & Future)
- by Geographic Region for United States, Europe, Asia-Pacific, Canada and Rest of World
- in US$ Million (Graphical Representation included)
- Exhibit 3: In Vivo ADME/Tox ( 2006, 2009 and 2012): Percentage Breakdown of
- Global Market Value by Geographic Region for United States, Europe, Asia-Pacific,
- Canada and Rest of World (Graphical Representation included)
- Exhibit 4: List of Major Global In Vivo Companies
- In Vitro ADME/Tox - An Emerging Technology
- Global Market Analysis
- Exhibit 5: In Vitro ADME/Tox (2005-2012) - Global Market Analysis (Current & Future)
- by Geographic Region for United States, Europe, Asia-Pacific, Canada and Rest of World
- in US$ Million (Graphical Representation included)
- Exhibit 6: In Vitro ADME/Tox ( 2006, 2009 and 2012): Percentage Breakdown of
- Global Market Value by Geographic Region for United States, Europe, Asia-Pacific,
- Canada and Rest of World (Graphical Representation included)
- Exhibit 7: List of Major Global In Vitro Companies
- In Silico ADME/Tox - The Fastest Growing Technology
- Global Market Analysis
- Exhibit 8: In Silico ADME/Tox (2005-2012) - Global Market Analysis (Current & Future)
- by Geographic Region for United States, Europe, Asia-Pacific, Canada and Rest of World
- in US$ Million (Graphical Representation included)
- Exhibit 9: In Silico ADME/Tox ( 2006, 2009 and 2012): Percentage Breakdown of
- Global Market Value by Geographic Region for United States, Europe, Asia-Pacific,
- Canada and Rest of World (Graphical Representation included)
- Exhibit 10: List of Major Global In Vitro Companies
- 4. Regional Market Analysis
- North America
- Exhibit 11: ADME/Tox Technologies (2005-2012) - North American Market Analysis
- (Current & Future) in US$ Million (Graphical Representation included)
- Analysis by Technology
- In Vivo
- Exhibit 12: In Vivo ADME/Tox (2005-2012) - North American Market Analysis
- (Current & Future) for United States and Canada
- in US$ Million (Graphical Representation included)
- Exhibit 13: In Vivo ADME/Tox ( 2006, 2009 and 2012): Percentage Breakdown of North
- American Market Value for United States and Canada
- In Vitro
- Exhibit 14: In Vitro ADME/Tox (2005-2012) - North American Market Analysis
- (Current & Future) for United States and Canada
- in US$ Million (Graphical Representation included)
- Exhibit 15: In Vitro ADME/Tox ( 2006, 2009 and 2012): Percentage Breakdown of
- North American Market Value for United States and Canada
- In Silico
- Exhibit 16: In Silico ADME/Tox (2005-2012) - North American Market Analysis
- (Current & Future) for United States and Canada
- in US$ Million (Graphical Representation included)
- Exhibit 17: In Silico ADME/Tox ( 2006, 2009 and 2012): Percentage Breakdown of
- North American Market Value for United States and Canada
- Europe
- Exhibit 18: ADME/Tox Technologies (2005-2012) - European Market Analysis
- (Current & Future) in US$ Million (Graphical Representation included)
- Analysis by Technology
- In Vivo
- Exhibit 19: In Vivo ADME/Tox Technologies (2005-2012) - European Market Analysis
- (Current & Future) by Geographic Region for UK, Germany, France, Sweden, Finland,
- Italy and Rest of Europe in US$ Million (Graphical Representation included)
- Exhibit 20: In Vivo ADME/Tox Technologies ( 2006, 2009 and 2012): Percentage
- Breakdown of European Market Value by Geographic Region for UK, Germany,
- France, Sweden, Finland, Italy and Rest of Europe (Graphical Representation included)
- In Vitro
- Exhibit 21: In Vitro ADME/Tox Technologies (2005-2012) - European Market Analysis
- (Current & Future) by Geographic Region for UK, Germany, France, Sweden, Finland,
- Italy and Rest of Europe in US$ Million (Graphical Representation included)
- Exhibit 22: In Vitro ADME/Tox Technologies ( 2006, 2009 and 2012): Percentage
- Breakdown of European Market Value by Geographic Region for UK, Germany,
- France, Sweden, Finland, Italy and Rest of Europe (Graphical Representation included)
- In Silico
- Exhibit 23: In Silico ADME/Tox Technologies (2005-2012) - European Market Analysis
- (Current & Future) by Geographic Region for UK, Germany, France, Sweden, Finland,
- Italy and Rest of Europe in US$ Million (Graphical Representation included)
- Exhibit 24: In Silico ADME/Tox Technologies ( 2006, 2009 and 2012): Percentage
- Breakdown of European Market Value by Geographic Region for UK, Germany,
- France, Sweden, Finland, Italy and Rest of Europe (Graphical Representation included)
- Asia-Pacific
- Exhibit 25: ADME/Tox Technologies (2005-2012) - Asia-Pacific Market Analysis
- (Current & Future) in US$ Million (Graphical Representation included)
- Analysis by Technology
- In Vivo
- Exhibit 26: In Vivo ADME/Tox (2005-2012) - Asia-Pacific Market Analysis
- (Current & Future) by Geographic Region for Japan, China, India, Australia, and
- Rest of Asia-Pacific in US$ Million (Graphical Representation included)
- Exhibit 27: In Vivo ADME/Tox Technologies ( 2006, 2009 and 2012): Percentage
- Breakdown of Asia-Pacific Market Value by Geographic Region for Japan, China,
- India, Australia and Rest of Asia-Pacific (Graphical Representation included)
- In Vitro
- Exhibit 28: In Vitro ADME/Tox (2005-2012) - Asia-Pacific Market Analysis
- (Current & Future) by Geographic Region for Japan, China, India, Australia, and
- Rest of Asia-Pacific in US$ Million (Graphical Representation included)
- Exhibit 29: In Vitro ADME/Tox Technologies ( 2006, 2009 and 2012): Percentage
- Breakdown of Asia-Pacific Market Value by Geographic Region for Japan, China,
- India, Australia and Rest of Asia-Pacific (Graphical Representation included)
- In Silico
- Exhibit 30: In Silico ADME/Tox (2005-2012) - Asia-Pacific Market Analysis
- (Current & Future) by Geographic Region for Japan, China, India, Australia,
- and Rest of Asia-Pacific in US$ Million (Graphical Representation included)
- Exhibit 31: In Silico ADME/Tox Technologies ( 2006, 2009 and 2012): Percentage
- Breakdown of Asia-Pacific Market Value by Geographic Region for Japan, China,
- India, Australia and Rest of Asia-Pacific (Graphical Representation included)
- Rest of World
- Exhibit 32: ADME/Tox Technologies (2005-2012) - Rest of World Market Analysis
- (Current & Future) in US$ Million (Graphical Representation included)
- III Products/Technology Research
- 1. ADME/TOX -The Basics
- Absorption
- Distribution
- Metabolism
- Excretion
- Toxicity
- Global ADME/TOX Market
- Exhibit 33: Global Market for ADME/Tox Technologies: Geographic Regions (Europe, Canada,
- United States, Asia-Pacific, and Rest of World) Ranked by Projected CAGR for
- 2005 through 2012 (Graphical Representation included)
- Factors Determined by ADME/TOX
- ADME/TOX Properties - Determined by
- The Increasing Need to Predict ADME/TOX Profiles
- Biological Assay Systems for the Evaluation of Cytochrome P450 Enzyme Isoforms
- Technologies for Lead Generation
- CommonTechnologies for Lead Generation Include
- Technologies for Preclinical Development of Drug Candidates
- Preclinical ADME/TOX Evaluation Tools
- Preclinical ADME/TOX Tools are Generally Validated for
- 2. ADME/Tox Methods
- High Throughput Screening
- Global HTS Market
- Exhibit 34: Global Market for HTS: Geographic Regions (Asia-Pacific, Europe, Canada,
- United States, and Rest of World) Ranked by Projected CAGR for 2005
- through 2012 (Graphical Representation included)
- Screening Technologies
- The Various Types of Screening Technologies
- Primary Screening
- Secondary Screening
- Biochemical Assays
- Cell based Assays
- High Content Screening
- Predictive Technologies
- Exhibit 35: Global Market for ADME/Tox Technologies: Predictive Technologies
- (In Silico, In Vitro and In Vivo) Ranked by Projected CAGR for
- 2005 through 2012 (Graphical Representation included)
- In Vivo ADMET
- Global In Vivo ADMET Market
- Exhibit 36: Global Market for In Vivo ADME/TOX Technologies: Geographic Regions,
- (Canada , Europe, US, Asia-Pacific and Rest of World Ranked by
- Projected CAGR for 2005 through 2012 (Graphical Representation included)
- Importance of In Vivo Tests
- Exhibit 37: In Vivo ADME/Tox Methods
- Modern In Vivo ADME/Tox Models
- Zebrafish
- Rodent Models
- Drosophila
- C.elegans
- Conventional In Vivo ADME/TOX Models
- Radiolabels
- Cassette Dosing
- Semi Simultaneous Dosing
- Why do we Need Animals for Trials?
- In Vitro ADMET
- Global In Vitro ADMET Market
- Exhibit 38: Global Market for In Vitro ADME/Tox Technologies: Geographic Regions
- (Canada , Europe, Asia-Pacific, US and Rest of World Ranked by Projected CAGR
- for 2005 through 2012 (Graphical Representation included)
- In Vitro Assays
- Veterinary In Vitro Testing
- Exhibit 39: Veterinary In Vitro Testing Technologies (2005-2012) - Global Value
- Analysis in US$ Million
- In Vitro Applications for Drug Discovery and Development
- Human and Animal Metabolism
- Permeation Studies
- Other ADME Services
- Exhibit 40: In Vitro ADME/TOX Methods
- Examples of Human In Vitro ADME/TOX Assays Include
- In Silico ADMET
- Global In Silico ADMET Market
- Exhibit 41: Global In Silico ADME/TOX Market: Geographic Regions (Europe,US,
- Asia- Pacific, Canada, and Rest of World Ranked by CAGR for 2005
- through 2012 (Graphical Representation included)
- In Silico Applications along Preclinical Stages
- Target Identification
- Lead Optimization
- Target Validation
- ADME/TOX Analysis
- In Silico Predictive Models
- Broad Segmentation of In Silico technology
- The Market For In Silico by Segment
- Exhibit 42: In Silico ADME/Tox (2005-2012) - Global Market Analysis by
- Segment for Organ and Tissue Cells, Cellular Networks, and Whole
- Cells in US$ Million (Graphical Representation included)
- Exhibit 43: In Silico ADME/TOX ( 2006, 2009 and 2012): Percentage Breakdown
- of Global Market Value by Segment for Organ and Tissue Cells,
- Cellular Networks, and Whole Cells (Graphical Representation included)
- Applications of In Silico Models in Drug Discovery Process
- Potential Applications of In Silico Technology
- Prediction of In Silico Profiles by Metabolic behavior
- The Market for In Silico Technologies
- The Prospects
- The Constraints
- 3. Toxicity
- Preclinical Toxicology
- Predictive Toxicology
- Determining Factors for Effective Predictive Toxicology in Preclinical Stage
- Remedial Measures
- Exhibit 44: Common Types of Toxicity Targeted for ADME/TOX Predictive Techniques
- Computational Toxicology
- QSAR
- In Vitro Toxicology
- In Vitro Toxicology - Liver Cell Models
- Tissue Culture Systems Used in In Vitro Toxicology
- In Vitro Toxicology Applications
- Genomics in Toxicity Testing
- Examining Neurotoxicity
- Exhibit 45: Common Approved In Vitro and In Vivo Procedures
- Alternatives for Animals in Toxicity Testing
- Exhibit 46: The Common Animals Used for ADME and Toxicity Testing
- (Graphical Representation included)
- Exhibit 47: Non-animal Methods being Considered for Validation
- 4. ADME/TOX - An Essence of Pharmaceutical Industry
- The Reasons for the Decline in Success Rates
- The Process of Drug Discovery
- Target Identification
- Target Validation
- Lead Identification
- Lead Optimization
- Clinical Trials
- Phase I
- Phase II
- Phase III
- Exhibit 48: The Critical Path for a Drug to Enter Clinical Trials
- Exhibit 49: Global Expenditure on Development and Approval of New Drugs:
2005 - 2012 (In US$ Million) (Graphical Representation included)
- Exhibit 50: Estimated Time Required for Development of Drugs by
Primary Indication (In Years) (Graphical Representation included)
- Exhibit 51: Global R & D Expenditure of Every New Chemical Entity (NEC)
Launched: 2005 to 2012 (In US$ Million) (Graphical Representation included)
- Exhibit 52: Drug Developmental Costs by Phase (Pre-approval)
(Graphical Representation included)
- 5. ADME/TOX in Drug Discovery Process
- Stages in Preclinical Studies
- The Factors Influencing Drug Approval Rates
- Exhibit 53: New Drug Attrition Rate: Percentage Breakdown of Factors Contributing to
- New Drug Failure for Inaptancy of Bioavailability, Toxicity, Commercial Drawbacks
- and Other (Graphical Representation included)
- Exhibit 54: Attrition of Compounds from Discovery to Launch Phase of a Drug
- (In number of compounds) (Graphical Representation included)
- Overlapping of Predictive ADME/TOX Technologies
- Applications by Technology
- Exhibit 55: Overlapping of Predictive ADME/TOX Technology Applications Across
- Various Stages of Drug Discovery (Graphical Representation included)
- 6. ADME/TOX and Drug Discovery Technologies
- Pharmacogenomics
- Pharmacokinetics
- A - Category
- D - Category
- M - Category
- E - Category
- Exhibit 56: Classification of Protein Targets by Category
- Proteomics
- Bioinformatics
- 7. Challenges Facing the ADME/TOX Industry
- IV. Market Dynamics
- 1. Global Market Analysis
- Exhibit 57: ADME/Tox Technologies (2005-2012) - Global Market Analysis
- (Current & Future) by Geographic Region for United States, Europe, Asia-Pacific,
- Canada and Rest of World in US$ Million (Graphical Representation included)
- Exhibit 58: ADME/Tox Technologies ( 2006, 2009 and 2012): Percentage Breakdown of
- Global Market Value by Geographic Region for United States, Europe, Asia-Pacific,
- Canada and Rest of World (Graphical Representation included)
- Global Markets in Related Technologies
- Laboratory Information Management Systems
- Global Market for LIMS
- Exhibit 59: Laboratory Information Management System (LIMS) (2005-2012) -
- Global Market Analysis (Current & Future) in US$ Million
- (Graphical Representation included)
- High Throughput Screening
- Global HTS Market
- Exhibit 60: High Throughput Screening (HTS) (2005-2012) - Global Market Analysis
- (Current & Future) in US$ Billion (Graphical Representation included)
- HTS Analysis by Geographic Region
- Exhibit 61: High Throughput Screening (HTS) (2005-2012) - Global Market Analysis
- (Current & Future) by Geographic Region for United States, Europe, Asia-Pacific,
- Canada and Rest of World in US$ Million (Graphical Representation included)
- Exhibit 62: High Throughput Screening (HTS) ( 2006, 2009 and 2012): Percentage
- Breakdown of Global Market Value by Geographic Region for United States, Europe,
- Asia-Pacific, Canada and Rest of World (Graphical Representation included)
- Global Market for HTS Products
- Exhibit 63: HTS Products (2005-2012) - Global Market Analysis
- (Current & Future) in US$ Million (Graphical Representation included)
- Global Market for Re-Screening of Hits
- Exhibit 64: Re-Screening of Hits (2005-2012) - Global Market Analysis
- (Current & Future) in US$ Million (Graphical Representation included)
- Global Market for HTS Services and Consumables
- Exhibit 65: HTS Services and Consumables (2005-2012) - Global Market Analysis
- (Current & Future) in US$ Billion (Graphical Representation included)
- Global Market for HTS Services and Call Based Consumables
- Exhibit 66: HTS Services and Cell Based Consumables (2005-2012) - Global Market
- Analysis (Current & Future) in US$ Billion (Graphical Representation included)
- Global Spending on HTS for Lead Discovery
- Exhibit 67: High Throughput Screening (HTS) (2005-2012) - Analysis of Global Spending
- for Lead Discovery by Geographic Region for United States, Europe, and Rest of World
- in US$ Billion (Graphical Representation included)
- Exhibit 68: High Throughput Screening (HTS) ( 2006, 2009 and 2012): Percentage
- Breakdown of Global Value of Spending for Lead Discovery by Geographic
- Region for United States, Europe, Asia-Pacific, Canada and Rest of World
- (Graphical Representation included)
- Cell Based Assays
- Global Market for Cell Based Assays
- Exhibit 69: Cell-Based Assays (2005-2012) - Global Market Analysis
- (Current & Future) in US$ Million (Graphical Representation included)
- Cell Based Assay Analysis by Geographic Region
- Exhibit 70: Cell-Based Assays (2005-2012) - Global Market Analysis (Current & Future)
- by Geographic Region for United States, Europe, Asia-Pacific, Canada and
- Rest of World in US$ Million (Graphical Representation included)
- Exhibit 71: Cell-Based Assays ( 2006, 2009 and 2012): Percentage Breakdown of
- Global Market Analysis (Current & Future) by Geographic Region for United States,
- Europe, Asia-Pacific, Canada and Rest of World (Graphical Representation included)
- Global Pharmaceutical Cell Based Screening Market
- Exhibit 72: Pharmaceutical Cell-Based Screening (2005-2012) - Global Market Analysis
- (Current & Future) in US$ Billion (Graphical Representation included)
- Global Drug Discovery Market
- Global Drug Discovery Expenditure
- Exhibit 73: Drug Discovery (2005-2012) - Global Expenditure
- in US$ Billion (Graphical Representation included)
- Global Biotech Industry at a Glance
- Major Research Areas in Biotechnology
- Exhibit 74: Global Biotechnology Industry (2005): Percentage Breakdown
- of Major Research Areas (Graphical Representation included)
- 2. The Need of the Hour
- 3. ADME/Tox - The Emerging Trends
- 4. Major Companies in ADME/Tox Industry
- Accelrys, Inc. (USA)
- ADMET Technologies (USA)
- Advanced Chemistry Development, Inc. (ACD/Labs) (Canada)
- Agilent Technologies, Inc. (USA)
- AMRI Hungary, Inc. (Hungary)
- Applied Biosystems Group (USA)
- Argenta Discovery Ltd. (UK)
- ArQule, Inc. (USA)
- Aureus Pharma (France)
- Bayer Technology Services GmbH (Germany)
- BD Biosciences (USA)
- Biacore International AB (Sweden)
- Bio-Rad Laboratories, Inc. (USA)
- Bridge Pharmaceuticals (USA)
- Caliper Life Sciences, Inc. (USA)
- Cellomics, Inc. (USA)
- Celsis International plc (UK)
- Cerep SA (France)
- Charles River Laboratories, Inc. (USA)
- ChemSilico LLC (The) (USA)
- Chenomx, Inc. (Canada)
- CompuDrug International, Inc. (USA)
- Cyprotex plc (UK)
- Gene Logic, Inc. (USA)
- Iconix Pharmaceuticals, Inc. (USA)
- ID Business Solutions Ltd. (UK)
- Invitrogen, Inc. (USA)
- Kendle International, Inc. (USA)
- Kibron, Inc. (Finland)
- LHASA Ltd. (UK)
- MDL Information Systems (USA)
- Millipore Corporation (USA)
- Molecular Discovery Ltd. (UK)
- MultiCASE, Inc. (USA)
- Noray Bioinformatics S.L. (Spain)
- Perkin Elmer, Inc. (USA)
- Pharma Algorithms (Canada)
- Promega Corporation (USA)
- Qualyst, Inc. (USA)
- Ranbaxy Laboratories Ltd. (India)
- Schrodinger LLC (USA)
- Simulations Plus, Inc. (USA)
- Sirius Analytical Instruments Ltd. (UK)
- Stem Cell Innovations, Inc. (USA)
- Strand Life Sciences (India)
- Sygnis Pharm AG (Germany)
- Tecan AG (Switzerland)
- Thermo Fisher Scientific, Inc. (USA)
- Tripos, Inc. (USA)
- Waters Corporation (USA)
- Xceleron Ltd. (UK)
- 5. Major Activities In ADME/Tox Industry
- Gene Logic Divests Genomics Assets and Changes Corporate Identity
- ChemDiv Extends Partnership Agreement with NMSI
- Medivir Gives New Structure to Drug Discovery
- Entelos, Inc. Agrees to Acquire Iconix Biosciences, Inc
- Cerep Sells Hesperion AG Business to Averion International
- BioFocus DPI Brings Further Advancement to ADME Optimization Services
- Symyx Technologies Closes Acquisition of MDL Information Systems
- Simulations Plus Signs Research Agreement with Enslein
- Gene Logic Enters into Alliance with FDA
- Gene Logic Enters into Alliance with Solvay Pharmaceuticals to Trace New Development
- Channels for Multiple Clinical Drug Candidates
- Amgen Concludes Ilypsa Acquisition
- Waters Corporation Signs Collaborative Agreement with Umetrics AB
- TetraQ gains GLP status for the ADME laboratory from NATA
- Waters Corporation to Collaborate with Dotmatics Limited
- Aureus Pharma Partners with MDL® Isentris® Alliance
- Galapagos Enters into Alliance with AstraZeneca for Novel Drug Discovery
- Galapagos Collaborates with Ono Pharmaceutical
- Lexicon Genetics Adopts New Corporate Identity
- Avista Capital Acquires BioReliance Corporation
- VASTox plc Acquires Dextra Laboratories and DanioLabs
- Takeda Pharmaceutical Acquires Paradigm Therapeutics Limited
- MDS Acquires Entire Stake in MDC
- Thermo Fisher Scientific Acquires Cohesive Technologies
- Qualyst and InterMune in B-CLEAR® Technology Licensing Deal
- LION bioscience Adopts New Identity
- PerkinElmer Acquires Euroscreen Products and Evotec Technologies
- Galapagos Acquires Inpharmatica
- Invitrogen Acquires Sentigen
- Affymetrix and Iconix Launch ToxFXTM
- MPI Research Takes Over Exygen Research
- Accium BioSciences Forms Strategic Alliance with CMIC
- Pharma Algorithms Unveils ADME Boxes version 3.5
- Covance Licenses B-CLEAR® From Qualyst, Inc
- Northwest Kinetics, Inc. Acquired by Charles River Laboratories
- Strand Life Sciences forms Partnership with BioIT Alliance
- Agilent Signs Agreement with Mass Consortium
- Calando Picks Agilent for siRNA production
- Origenis Becomes First Customer to Aureus Pharma's AurWEB
- Invitrogen Pockets TEF Product Lines
- Odyssey Forms Alliance with Pfizer
- Agilent Bags CGH Microarray License from Abbott
- Celsis Acquires In Vitro Technologies
- Cohesive Collaborates with Mayo Clinic
- CHDI Partners with Evotec
- Hesperion Takes Over Touchstone
- Iconix Inks Services Agreement with Merck
- BioDynamics Partners with Noray
- DAC Inks Agreement with Evotec
- Millipore acquires Serologicals
- Aureus Pharma Issues License on AurSCOPE
- Aureus Pharma Issues License on hERG and AurSCOPE ADME
- Boehringer Bags MetaCore License from GeneGo
- NovaScreen Bags HTS Contract from Wyeth
- Ingenuity Signs Integration Agreement with Agilent
- Bio-Rad Collaborates with Infometrix
- BioWisdom Takes Over Bioinformatics Business of LION
- BGM Forms Collaboration with Mitsubishi Pharma
- Iconix Broadens Toxicogenomics Gene Expression Database
- Qualyst and Oxford Biomedical Research in License Agreement for ACCURATE
- PerkinElmer signs xMap licensing agreement with Luminex
- Genospectra Merges with Panomics
- Affymetrix Enters into Collaboration with Iconix
- Varian Bags FTMS Technology
- Evotec Bags HCS Patent License from Cellomics
- Tripos and InforSense enter into Informatics Alliance
- Xceleron Inks Collaborative Agreement with Servier
- Iconix Forms Collaboration with Eli Lilly
- Strand Life Sciences and Elan Enter into Collaboration
- TetraQ forms Alliance with Ground Zero Pharmaceuticals
- BGM Conducts Joint Toxicity Study with FDA
- Qualyst and SC BioSciences Announce B-CLEAR® Marketing alliance in Japan
- Simulations Plus Acquires Sage Informatics
- Xceleron Enters into Preferred Supply Agreement with GSK
- Bio-Rad Enters into Collaboration with Equbits and Aureus Pharma
- 6. Major Product Introductions/Developments in ADME/Tox Industry
- Pharma Algorithms Releases New ADME Boxes Version 4.0
- Simulations Plus Releases New Important Upgrade of ClassPharmer Software
- Applied Biosystems and Sciex Jointly Launch the New Cliquid Drug Screen and
- Quant Software for Application in Routine Forensic Toxicology
- BioReliance Introduces Novel Genotoxicity Screening Service
- Caliper Life Sciences Introduces CDAS for Offering Complete Drug Discovery and
- Development Services
- Simulations Plus Introduces New DNA Mutation Predictor
- Simulations Plus Launches ADMET Predictor Version 2.3
- Pharma Algorithms Announces ToxBox Version 2.0
- Aureus Pharma Introduces New Tool to Identify Risks of Drug-Drug Interactions
- DTEx - New technology for Gene Expression Profiling for Drugs
- Strand Introduces New Platform for In Silico Lead Optimization
- NMS Introduces the New Brand Accelera
- Simulations Plus Introduces New Predictive Models Expected to Improve Anti-HIV
- Activity Discovery Capability
- InterMune Employs B-CLEAR Technology for Drug Discovery Applications
- Quantum Pharmaceuticals Releases an Innovative Platform
- Agilent Launches Oligo array based Chip-on-chip Microarrays
- Invitrogen Launches Advanced Transfection Reagents
- Thermo Electron (Thermo Fisher Scientific) Introduces Updates to Darwin LIMS
- Accelrys Introduces Discovery Studio® 1.6
- Bio-Rad releases version 7.5 of its KnowItAll Informatics System
- Applied Biosystems and GeneGo Enter into Collaboration for Tissue Gene Expression
- Aureus Pharma Unveils AurSCOPE® Kinase
- Bionas Launches In Vitro Profiling Device
- Caliper Unveils Xenogen
- Genetix Produces CloneFill
- Genetix Introduces Cell Dispense
- Millipore Introduces 96-Well Millicell Plate
- Peakdale Launches Peakfinder® Kinase Arrays
- Applied Biosystems Adds a Million Genotyping Assays to Its TaqMan® Collection
- Invitrogen Signs Agreement to Add ClonepixFL Technology of Genetix to Process
- Development Services
- Aureus Pharma Issues License on AurSCOPE
- Aureus Pharma Issues License on hERG and AurSCOPE ADME
- Simulations Plus Launches Latest Versions of ADMET Software
- Schrödinger Updates Schrödinger Suite 2006
- Thermo Electron (Thermo Fisher Scientific) Launches Galileo LIMS v 3.2
- Bio-Rad Incorporates MolSAR Technology into KnowItAll
- Malvern Instruments' Zetasizer Nano S Selected For Drug Delivery Research Use
- Inpharmatica Expands Admensa Interactive Drug Discovery Tools
- Peakdale Announces Completion of Peakexplorer GPCR Collection
- SSi Robotic's FLASH System Selected by Invitrogen
- Gene Logic Introduces ASCENTA® System 2.0
- ReNeuron Develops Human Hepatocyte Cell Lines
- Spotfire Launches Microarray Application
- GeneGo Combines MetaDrug and Accelrys' Accord Technology
- Bioreason Unveils ClassPharmer Suite
- GE Healthcare Releases ADME Rat Microarray
- Millipore and Caliper Develop HT Protocols
- Waters Introduces Waters® MassTrak
- Bio-Rad Laboratories Inc., Introduces ADMET Databases
- Molecular Devices Corporation Launches Assay Kits for Early ADME Screening Thermo Electron (Thermo Fisher Scientific) Introduces LeadStream ADME/Tox Solution
- Beckman Coulter Inc., Launches Biomek FX ADMETox Workstation
- 7. Regional Market Analysis
- A. The United States
- US Market Analysis
- Exhibit 75: ADME/Tox Technologies (2005-2012) - United States Market Analysis
- (Current & Future) in US$ Million (Graphical Representation included)
- Exhibit 76: List of Major Companies in The United States
- Exhibit 77: ADME/Tox Technologies (2005-2012) - United States Market Analysis
- (Current & Future) by Predictive Technology for In Vivo, In Vitro and In
- Silico in US$ Million (Graphical Representation included)
- Exhibit 78: ADME/Tox Technologies ( 2006, 2009 and 2012): Percentage
- Breakdown of United States Market Value by Predictive Technology for
- In Vivo, In Vitro and In Silico (Graphical Representation included)
- Market for Related Technologies in The United States
- US Market for HTS
- Exhibit 79: High Throughput Screening (HTS) (2005-2012) - United States Market
- Analysis (Current & Future) in US$ Billion (Graphical Representation included)
- US Spending on HTS for Lead Discovery
- Exhibit 80: High Throughput Screening (HTS) (2005-2012) - United States Spending
- for Lead Discovery in US$ Million (Graphical Representation included)
- US Market for Cell Based Assays
- Exhibit 81: Cell-Based Assay (2005-2012) - United States Market Analysis
- (Current & Future) in US$ Million (Graphical Representation included)
- US Market for Pharma Contract Research
- Exhibit 82: Pharmaceutical Contract Research (2005-2012) - United States Market
- Analysis (Current & Future) in US$ Million (Graphical Representation included)
- Exhibit 83: Number of Drugs with Potential Approval in the United States:
- 2005 - 2006 Estimates (Graphical Representation included)
- B. Canada
- Exhibit 84: ADME/Tox Technologies (2005-2012) - Canadian Market Analysis
- (Current & Future) in US$ Million (Graphical Representation included)
- Exhibit 85: List of Major Companies in Canada
- Exhibit 86: ADME/Tox Technologies (2005-2012) - Canadian Market Analysis
- (Current & Future) by Predictive Technology for In Vivo, In Vitro and In Silico
- in US$ Million (Graphical Representation included)
- Exhibit 87: ADME/Tox Technologies ( 2006, 2009 and 2012): Percentage Breakdown
- of Canadian Market Value by Predictive Technology for In Vivo, In Vitro and
- In Silico (Graphical Representation included)
- Market for Related Technologies in Canada
- Canadian Market for HTS
- Exhibit 88: High Throughput Screening (HTS) (2005-2012) - Canadian Market Analysis
- (Current & Future) in US$ Million (Graphical Representation included)
- Canadian Market for Cell Based Assays
- Exhibit 89: Cell-Based Assay (2005-2012) - Canadian Market Analysis
- (Current & Future) in US$ Million (Graphical Representation included)
- Canadian Market for Biotech R&D
- Exhibit 90: Biotechnology R&D Expenditure (2005-2012) - Canadian Market Analysis
- (Current & Future) in US$ Million (Graphical Representation included)
- C. Europe
- Exhibit 91: ADME/Tox Technologies (2005-2012) - European Market Analysis
- (Current & Future) in US$ Million (Graphical Representation included)
- Exhibit 92: List of Major Companies in Europe
- Analysis by Geographic Region
- Exhibit 93: ADME/Tox Technologies (2005-2012) - European Market Analysis
- (Current & Future) by Geographic Region for UK, Germany, France, Sweden,
- Finland, Italy and Rest of Europe in US$ Million (Graphical Representation included)
- Exhibit 94: ADME/Tox Technologies ( 2006, 2009 and 2012): Percentage Breakdown
- of European Market Value by Geographic Region for UK, Germany, France, Sweden,
- Finland, Italy and Rest of Europe (Graphical Representation included)
- Analysis by Segment
- Exhibit 95: ADME/Tox Technologies (2005-2012) - European Market Analysis
- (Current & Future) by Segment for Services and Technology in
- US$ Million (Graphical Representation included)
- Exhibit 96: ADME/Tox Technologies ( 2006, 2009 and 2012): Percentage
- Breakdown of European Market Value by End-Use Sector for
- Services and Technology (Graphical Representation included)
- Analysis by Technology
- Exhibit 97: ADME/Tox Technologies (2005-2012) - European Market Analysis
- (Current & Future) by Predictive Technology for In Vivo, In Vitro and
- In Silico in US$ Million (Graphical Representation included)
- Exhibit 98: ADME/Tox Technologies ( 2006, 2009 and 2012): Percentage Breakdown
- of European Market Value by Predictive Technology for In Vivo, In
- Vitro and In Silico (Graphical Representation included)
- Market for Related Technologies in Europe
- European Market for HTS
- Exhibit 99: High Throughput Screening (HTS) (2005-2012) - European Market Analysis
- (Current & Future) in US$ Billion (Graphical Representation included)
- European Spending on HTS for Lead Discovery
- Exhibit 100: High Throughput Screening (HTS) (2005-2012) - European Spending for
- Lead Discovery in US$ Billion (Graphical Representation included)
- European Market for Cell Based Assays
- Exhibit 101: Cell-Based Assay (2005-2012) - European Market Analysis
- (Current & Future) in US$ Million (Graphical Representation included)
- European Market for Drug Discovery
- Exhibit 102: Drug Discovery (2005-2012) - European Market Analysis
- (Current & Future) in US$ Billion (Graphical Representation included)
- European Market for Drug Discovery Outsourcing
- Exhibit 103: Drug Discovery Outsourcing (2005-2012) - European Market Analysis
- (Current & Future) in US$ Billion (Graphical Representation included)
- European Market for Nanotechnology Based Drug Discovery
- Exhibit 104: Drug Discovery Based on Nanotechnology (2005-2012) - European Market
- Analysis (Current & Future) in US$ Million (Graphical Representation included)
- European Biotechnology Market
- Exhibit 105: Biotechnology R&D Expenditure (2005-2012) - European Market Analysis
- (Current & Future) in US$ Billion (Graphical Representation included)
- European ADME/Tox Market by Country
- C1. The United Kingdom
- Major Companies in UK ADME/Tox Market
- UK Marker Analysis
- Exhibit 106: ADME/Tox Technologies (2005-2012) - UK Market Analysis
- (Current & Future) by Predictive Technology for In Vivo, In Vitro and
- In Silico in US$ Million (Graphical Representation included)
- Exhibit 107: ADME/Tox Technologies ( 2006, 2009 and 2012): Percentage Breakdown
- of UK Market Value by Predictive Technology for In Vivo, In
- Vitro and In Silico (Graphical Representation included)
- C2. Germany
- Major Companies in German ADME/Tox Market
- German Market Analysis
- Exhibit 108: ADME/Tox Technologies (2005-2012) - German Market Analysis
- (Current & Future) by Predictive Technology for In Vivo, In Vitro and
- In Silico in US$ Million (Graphical Representation included)
- Exhibit 109: ADME/Tox Technologies ( 2006, 2009 and 2012): Percentage Breakdown
- of German Market Value by Predictive Technology for In Vivo,
- In Vitro and In Silico (Graphical Representation included)
- C3. France
- Major Companies in French ADME/Tox Market
- French Market Analysis
- Exhibit 110: ADME/Tox Technologies (2005-2012) - French Market Analysis
- (Current & Future) by Predictive Technology for In Vivo, In Vitro and
- In Silico in US$ Million (Graphical Representation included)
- Exhibit 111: ADME/Tox Technologies ( 2006, 2009 and 2012): Percentage
- Breakdown of French Market Value by Predictive Technology for In Vivo,
- In Vitro and In Silico
- C4. Finland
- Major Companies in Finnish ADME/Tox Market
- Finnish Market Analysis
- Exhibit 112: ADME/Tox Technologies (2005-2012) - Finnish Market Analysis
- (Current & Future) by Predictive Technology for In Vivo, In Vitro and
- In Silico in US$ Million (Graphical Representation included)
- Exhibit 113: ADME/Tox Technologies ( 2006, 2009 and 2012): Percentage
- Breakdown of Finnish Market Value by Predictive Technology for In Vivo,
- In Vitro and In Silico
- C5. Italy
- Major Companies in Italian ADME/Tox Market
- Italian Market Analysis
- Exhibit 114: ADME/Tox Technologies (2005-2012) - Italian Market Analysis
- (Current & Future) by Predictive Technology for In Vivo, In Vitro and
- In Silico in US$ Million (Graphical Representation included)
- Exhibit 115: ADME/Tox Technologies ( 2006, 2009 and 2012): Percentage
- Breakdown of Italian Market Value by Predictive Technology for In Vivo,
- In Vitro and In Silico
- C6. Sweden
- Major Company in Swedish ADME/Tox Market
- Swedish Market Analysis
- Exhibit 116: ADME/Tox Technologies (2005-2012) - Swedish Market Analysis
- (Current & Future) by Predictive Technology for In Vivo, In Vitro and
- In Silico in US$ Million (Graphical Representation included)
- Exhibit 117: ADME/Tox Technologies ( 2006, 2009 and 2012): Percentage
- Breakdown of Swedish Market Value by Predictive Technology for In Vivo,
- In Vitro and In Silico
- C7. Rest of Europe
- Analysis by Geographic Region
- Exhibit 118: ADME/Tox Technologies (2005-2012) - Rest of Europe Market Analysis
- (Current & Future) by Geographic Region for Switzerland, Hungary, Belgium, Austria,
- Spain and Other in US$ Million (Graphical Representation included)
- Exhibit 119: ADME/Tox Technologies ( 2006, 2009 and 2012): Percentage Breakdow of Rest of Europe Market Value by Geographic Region for Switzerland, Hungary,
- Belgium, Austria, Spain and Other
- Analysis by Technology
- Exhibit 120: ADME/Tox Technologies (2005-2012) - Rest of Europe Market Analysis
- (Current & Future) by Predictive Technology for In Vivo, In Vitro and In
- Silico in US$ Million (Graphical Representation included)
- Exhibit 121: ADME/Tox Technologies ( 2006, 2009 and 2012): Percentage
- Breakdown of Rest of Europe Market Value by Predictive Technology for
- In Vivo, In Vitro and In Silico
- D. Asia-Pacific
- Exhibit 122: ADME/Tox Technologies (2005-2012) - Asia-Pacific Market Analysis
- in US$ Million (Graphical Representation included)
- Exhibit 123: List of Major Companies in Asia-Pacific
- Analysis by Geographic Region
- Exhibit 124: ADME/Tox Technologies (2005-2012) - Asia-Pacific Market Analysis
- (Current & Future) by Geographic Region for Japan, China, India, Australia
- and Rest of Asia-Pacific in US$ Million (Graphical Representation included)
- Exhibit 125: ADME/Tox Technologies ( 2006, 2009 and 2012): Percentage Breakdown of
- Asia-Pacific Market Value by Geographic Region for Japan, China, India, Australia
- and Rest of Asia-Pacific
- Analysis by Technology
- Exhibit 126: ADME/Tox Technologies (2005-2012) - Asia-Pacific Market Analysis
- (Current & Future) by Predictive Technology for In Vivo, In Vitro and
- In Silico in US$ Million (Graphical Representation included)
- Exhibit 127: ADME/Tox Technologies ( 2006, 2009 and 2012): Percentage Breakdown
- of Asia-Pacific Market Value by Predictive Technology for In Vivo,
- In Vitro and In Silico
- Drug Discovery Scenario in Asia-Pacific
- Asia-Pacific Market for HTS
- Exhibit 128: High Throughput Screening (HTS) (2005-2012) - Asia-Pacific
- Market Analysis (Current & Future) in US$ Million (Graphical Representation included)
- Asia-Pacific Market for Drug Discovery
- Exhibit 129: Drug Discovery (2005-2012) - Asia-Pacific Market Analysis
- (Current & Future) in US$ Billion (Graphical Representation included)
- Asia-Pacific Market for Pharma CROs
- Exhibit 130: Pharmaceutical Contract Research Organization (CROs) (2005-2012) -
- Asia-Pacific Market Analysis (Current & Future) in US$ Billion
- (Graphical Representation included)
- Asia-Pacific ADME/Tox Market by Country
- D1. Japan
- Major Companies in Japanese ADME/Tox Market
- Japanese Market Analysis
- Exhibit 131: ADME/Tox Technologies (2005-2012) - Japanese Market Analysis
- (Current & Future) by Predictive Technology for In Vivo, In Vitro and
- In Silico in US$ Million (Graphical Representation included)
- Exhibit 132: ADME/Tox Technologies ( 2006, 2009 and 2012): Percentage
- Breakdown of Japanese Market Value by Predictive Technology for In Vivo,
- In Vitro and In Silico
- D2. China
- Major Companies in Chinese ADME/Tox Market
- Chinese Market Analysis
- Exhibit 133: ADME/Tox Technologies (2005-2012) - Chinese Market Analysis
- (Current & Future) by Predictive Technology for In Vivo, In Vitro and
- In Silico in US$ Million (Graphical Representation included)
- Exhibit 134: ADME/Tox Technologies ( 2006, 2009 and 2012): Percentage
- Breakdown of Chinese Market Value by Predictive Technology for In Vivo,
- In Vitro and In Silico
- D3. India
- Major Companies in Indian ADME/Tox Market
- Indian Market Analysis
- Exhibit 135: ADME/Tox Technologies (2005-2012) - Indian Market Analysis
- (Current & Future) by Predictive Technology for In Vivo, In Vitro and
- In Silico in US$ Million (Graphical Representation included)
- Exhibit 136: ADME/Tox Technologies ( 2006, 2009 and 2012): Percentage
- Breakdown of Indian Market Value by Predictive Technology for In Vivo,
- In Vitro and In Silico
- D4. Australia
- Australian Market Analysis
- Exhibit 137: ADME/Tox Technologies (2005-2012) - Australian Market Analysis
- (Current & Future) by Predictive Technology for In Vivo, In Vitro and
- In Silico in US$ Million (Graphical Representation included)
- Exhibit 138: ADME/Tox Technologies ( 2006, 2009 and 2012): Percentage
- Breakdown of Australian Market Value by Predictive Technology for In Vivo,
- In Vitro and In Silico (Graphical Representation included)
- D5. Rest of Asia-Pacific
- Rest of Asia-Pacific Market Analysis
- Analysis by Geographic Region
- Exhibit 139: ADME/Tox Technologies (2005-2012) - Rest of Asia-Pacific
- Market Analysis (Current & Future) by Geographic Region for
- South Korea, Singapore, Hong Kong and Other in US$ Million
- (Graphical Representation included)
- Exhibit 140: ADME/Tox Technologies ( 2006, 2009 and 2012): Percentage
- Breakdown of Rest of Asia-Pacific Market Value by Geographic Region
- South Korea, Singapore, Hong Kong and Other (Graphical Representation included)
- Analysis by Technology
- Exhibit 141: ADME/Tox Technologies (2005-2012) - Rest of Asia-Pacific
- Market Analysis (Current & Future) by Predictive Technology for In Vivo,
- In Vitro and In Silico in US$ Million (Graphical Representation included)
- Exhibit 142: ADME/Tox Technologies ( 2006, 2009 and 2012): Percentage
- Breakdown of Rest of Asia-Pacific Market Value by Predictive Technology
- for In Vivo, In Vitro and In Silico (Graphical Representation included)
- E. Rest of World
- Latin America
- Middle East
- Africa
- Exhibit 143: List of Major Companies in Rest of World
- Rest of World Market Analysis
- Exhibit 144: ADME/Tox Technologies (2005-2012) - Rest of World Market Analysis
- (Current & Future) by Predictive Technology for In Vivo, In Vitro and
- In Silico in US$ Million (Graphical Representation included)
- Exhibit 145: ADME/Tox Technologies ( 2006, 2009 and 2012): Percentage
- Breakdown of Rest of Asia-Pacific Market Value by Predictive Technology for
- In Vivo, In Vitro and In Silico (Graphical Representation included)
- 8. ADME/Tox Technologies - The Industry Outlook
- V. Corporate Directory
|
|
|
